Long-term Prognosis and Quality of Life in Early Rheumatoid Arthritis Patients Treated by 2015 ACR Guideline (LELAND)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-05-13

Study Completion Date

2022-07-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To focus on the real world treat-to-target rate of early rheumatoid arthritis patients who will be treated according to the 2015 American College of Rheumatology Guideline for the Treatment of RA.

To explore the factors which influence the treat-to-target outcome.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effects of HMG-coA Reductase Inhibitor on Rheumatoid Arthritis

NCT00555230

Rheumatoid Arthritis

COMPLETED PHASE2

Factors Affecting Hand Dysfunction in Patient With Rheumatoid Arthritis and Its Correlation With Quality of Life

NCT03274570

Rheumatoid Arthritis

UNKNOWN

Role of L-Arginine Supplementation in the Treatment of Rheumatoid Arthritis

NCT04535427

Rheumatoid Arthritis

UNKNOWN PHASE2

Rheumatoid Arthritis Real-world Cohort Study in China (ReALSA)

NCT06233929

Rheumatoid Arthritis

ACTIVE_NOT_RECRUITING

Study of Some Risk Factors for Developing RA

NCT03624179

Rheumatoid Arthritis

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Resent study showed that rapid progression of cartilage and bone damage could happen on the early state of RA patients, so the clinicians should try the best to stop the trend, such as early diagnosis, early treatment and treat-to-target. But only half of the RA patients could reach low disease activity in the whole world and about 10% in China.

The investigators enroll early RA patients who are treated according to the 2015 American College of Rheumatology Guideline. The relevant data are collected and analyzed by the statistician including clinical data, imaging markers, blood samples and patient-reported outcomes every 3 months.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Rheumatoid Arthritis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

early RA patients

patients must fulfill the 1987 ACR classification criteria for rheumatoid arthritis or 2010 Rheumatoid arthritis classification criteria of ACR/EULAR, and meet the condition that the course of disease was no more than 6 months. If enrolled, patients will be treated with disease modified antirheumatic drugs or biological agents.

disease modified antirheumatic drugs or biological agents

Intervention Type DRUG

Enrolled patients will be treated according to the 2015 American College of Rheumatology Guideline for the Treatment of RA

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

disease modified antirheumatic drugs or biological agents

Enrolled patients will be treated according to the 2015 American College of Rheumatology Guideline for the Treatment of RA

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

DMARDs, MTX, biologics

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* ≥18 years,
* be diagnosed with RA according to the 1987 or 2010 ACR criteria,
* in the course of the disease within 6 months,
* fill out questionnaires by oneself,
* fully understand the survey, agree to take part in the survey with signing the informed consent, and authority the researchers to expose and use his or her personal health information.

Exclusion Criteria

* woman in pregnancy, lactation or plan to pregnant in the next 2 years,
* before enter this study, the patient joint any other RA clinical study in the past 24 weeks,
* according to the clinicians, one may not report his /or her life quality or the utilization of leading medical resources.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No